Methylprednisolone in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS)

NCT05986422 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

96

Enrollment

OTHER

Sponsor class

Stopped Following a recommendation from the Data Safety Monitoring Board (DSMB).

Conditions

Post-COVID-19 Syndrome

Interventions

DRUG: Methylprednisolone

Sponsor

Charite University, Berlin, Germany